Related Experiment Videos
Current treatments in neurology: stroke
1Clinical Neuroscience, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. h.markus@sghms.ac.uk
Journal of Neurology
|March 3, 2005
Summary
Recent advances in stroke treatment include thrombolysis for ischemic stroke within 3 hours and anticoagulants for cardioembolic stroke. Antiplatelet agents and carotid endarterectomy offer secondary prevention strategies for various stroke types.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Stroke treatment has significantly advanced due to large-scale clinical trials.
- Current strategies encompass both acute interventions and long-term secondary prevention.
Purpose of the Study:
- To review established and emerging treatments for ischemic stroke and secondary stroke prevention.
- To synthesize evidence from clinical trials regarding thrombolysis, anticoagulants, antiplatelet agents, and carotid endarterectomy.
Main Methods:
- Systematic review of evidence from major clinical trials on stroke treatment.
- Analysis of therapeutic benefits and risk-benefit ratios for various interventions.
Main Results:
- Thrombolysis is a standard acute treatment for ischemic stroke within 3 hours; trials are exploring extended windows.
- Anticoagulants are beneficial for cardioembolic stroke, especially with atrial fibrillation; antiplatelet agents show better risk-benefit for other subtypes.
- Carotid endarterectomy benefits symptomatic stenosis >70%, with earlier surgery preferred; its role in asymptomatic stenosis remains debated.
Conclusions:
- Evidence supports thrombolysis, anticoagulants, antiplatelet agents, and carotid endarterectomy in specific stroke scenarios.
- Ongoing research aims to optimize treatment windows and patient selection for acute and preventive therapies.
- Balancing risks and benefits is crucial for selecting secondary prevention strategies, with carotid endarterectomy for asymptomatic stenosis requiring further consideration.